Spark Investment Management’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
Other funds holding PLX
Spark Investment Management's PLX Position: Q3 2026 in Review
Spark Investment Management opened a new position in Protalix BioTherapeutics (PLX) in Q3 2026: 11,800 shares worth $32.6K. The stake represents 0.05% of the portfolio and ranks #117 among its holdings. This is a return to the name: Spark Investment Management previously reported a position in PLX as recently as Q4 2016.
Spark Investment Management first reported a position in PLX in Q2 2014 and has held it in 12 quarters since. The position peaked at $234K in Q4 2015. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.
- Spark Investment Management held 11,800 shares of Protalix BioTherapeutics worth $32.6K as of Q3 2026.
- Protalix BioTherapeutics was a new Spark Investment Management position in Q3 2026.
- Protalix BioTherapeutics made up 0.05% of Spark Investment Management's portfolio in Q3 2026, its #117 holding.
- Spark Investment Management first reported a position in Protalix BioTherapeutics in Q2 2014 and has held it in 12 quarters since.
- Spark Investment Management's Protalix BioTherapeutics position peaked at $234K in Q4 2015.
- 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.
Based on Spark Investment Management's 13F filing for Q3 2026, filed 13 Nov 2026.